Login Get Started
Browse
Shares
Healthcare
Biotechnology & Medical Research
Aprea Therapeutics Inc
Aprea Therapeutics Inc logo

APRE - Aprea Therapeutics Inc Reuters News

$6 -0.3  -5.1%

Last Trade - 25/02/21

Sector
Healthcare
RiskRating
Speculative
Size
Small Cap
Style
Sucker Stock
Market Cap £90.7m
Enterprise Value £18.5m
Revenue £n/a
Position in Universe 4840th / 6718
Quality
Value
Momentum
StockRank™
StockReport™
Tools
Compare with... Run through checklist
Accounts
Balance sheet Income statement Cashflow statement Dividend summary
Charts News Discussions APRE Dividends
Reuters News
All News Reuters News Company Announcements
BRIEF-Aprea Therapeutics Inc Sees Anticipated Cash Burn For 2021 Between $30 Mln And $35 Mln
12th Jan News
Aprea Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021
8th Jan News
BUZZ-U.S. STOCKS ON THE MOVE-Amphastar Pharma, Snap, Aprea Therapeutics
29th Dec '20 News
BUZZ-Street View: Failure of Aprea's cancer treatment quashes remaining bullish sentiments
29th Dec '20 News
U.S. RESEARCH ROUNDUP- Aprea Therapeutics, Beyondspring, Cognizant Technology
29th Dec '20 News
BUZZ-U.S. STOCKS ON THE MOVE-Lockheed Martin, stay-at-home stocks, COVID-19 vaccine makers
28th Dec '20 News
BUZZ-U.S. STOCKS ON THE MOVE-AMC Entertainment, UnitedHealth, Peabody Energy
28th Dec '20 News
BUZZ-U.S. STOCKS ON THE MOVE-U.S. airlines, Myovant Sciences, IMV, AMD
28th Dec '20 News
BUZZ-Aprea Therapeutics: Slumps after blood cancer treatment fails late-stage trial
28th Dec '20 News
NASDAQ RESUMED AT 08:31 AM
28th Dec '20 News
BRIEF-Aprea Therapeutics Announces Results From Phase 3 Trial Of Eprenetapopt In Myelodysplastic Syndromes
28th Dec '20 News
Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS)
28th Dec '20 News
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:59 AM
28th Dec '20 News
Aprea Therapeutics Receives FDA Fast Track Designation for Eprenetapopt in the Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)
30th Nov '20 News
Aprea Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference
19th Nov '20 News
BRIEF-Aprea Therapeutics Files For Mixed Shelf Of Upto $350 Mln
12th Nov '20 News
BRIEF-Aprea Therapeutics Reports Third Quarter 2020 Financial Results And Provides Update On Business Operations
5th Nov '20 News
Aprea Therapeutics Reports Third Quarter 2020 Financial Results and Provides Update on Business Operations
5th Nov '20 News
Aprea Therapeutics to Highlight Changing Treatment Paradigm in MDS as well as Development Pipeline Progress at Virtual R&D Day Today
30th Oct '20 News
Aprea Therapeutics Launches Disease Awareness Website for Healthcare Professionals, p53reactivation.com
14th Oct '20 News
© Stockopedia 2021, Refinitiv, Share Data Services.
Youtube Instagram RSS
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.